Based on our published data supporting higher expression of CCRL2 in MDS/AML, TP53-mutated disease and myeloid neoplasms with erythroid features compared to de novo AML (14, 16), 4 patients with de novo/TP53-wild-type AML, 4 patients with TP53-wild-type MDS-related AML and 10 patients with multi-hit TP53-mutated (complex karyotype with TP53 mutation with variant-allele frequency ≥ 50%) MDS/AML including 3 individuals with acute erythroid leukemia (Supplementary Tables 2, 3 andFig. 3A) were included. This evidence concerns the gene CCRL2 and myeloid neoplasm.